The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins the ...

MapLight Therapeutics is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The California-based ...

The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Good morning, Boston, and happy Friday. Here are the five ...

The U.S. IPO market roared back in 2025, as the 176 initial public offerings during the first half of the year matched the ...

Ming Yu was set up in 2018 by Cao Guoqing, a biochemist with an international profile in cutting-edge drug research. Cao ...

Jyong Biotech aims to raise $18.8 million in a US IPO. The company develops plant-based treatments for urinary diseases but faces FDA efficacy doubts and high legal cost exposure. Financially, Jyong ...

Not only has the window for biotech initial public offerings (IPOs) remained wide open so far this year, but also the after-market performance of the newly minted public companies has been nothing ...

Based on the last month's worth of biotech initial public offerings, the planned IPO of Proteon this week could be a struggle. Proteon Therapeutics of Waltham is tentatively set to go public tomorrow ...